I. Amendments to the Claims

The listing of claims shall replace all prior versions, and listings, of claims in the application.

1. (Currently Amended) A method of blocking or reducing allergic rhinitis ~~physiological reaction~~ in a mammal resulting from ~~to~~ the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) to treat allergic rhinitis, wherein the CnT is isolated or purified from a species of Clostridia selected from the group consisting of C. botulinum, C. butyricum and C. beratti ~~Clostridia sp~~.

2. (Original) The method of claim 1 wherein the mammal is a member of H. sapiens.

3. (Currently Amended) The method of claim 2 wherein the neurotoxin is isolated or purified from ~~a species of Clostridia selected from the group consisting of~~ C. botulinum~~, C. butyricum, C. beratti, and C. tetani~~.

4. (Currently Amended) The method of claim 3 wherein the neurotoxins (BoNT) are ~~purified or isolated from~~ serotypes A, B, C1, D, E, F or ~~and~~ G

5. (Cancelled)

6. (Original) The method of claim 1 wherein CnT is administered by contact with absorbant pledgets having CnT absorbed thereon.

7. (Original) The method of claim 1 wherein CnT is administered by contact with biodegradable carrier containing CnT.

8. (Original) The method of claim 1 wherein CnT is administered by injection.

9. (Currently Amended) The method of claim 1 wherein CnT is administered by myringotomy through ~~into~~ tympanic membranes.

10. (Original) The method of claim 1 wherein CnT is administered by injection into the pterygoplatine space through the palate.

11. (Original) The method of claim 7 wherein CnT is administered to pass through the nasal wall to the sphenopalatine ganglia.

12. (Previously Presented) The method of claim 1 wherein CnT is administered by inhalation of an aqueous mist containing same.

13. (Original) The method of claim 1 wherein CnT is administered by injection to the nasal mucosa.

14. (Previously Presented) The method of claim 1 wherein CnT is administered by application of a suppository containing same.

15. (Currently Amended) The method of claim 1 wherein the CnT directly blocks neuroimmune secretions from mast cells, eosinophils or B-lymphocytes ~~physiological reaction is manifested by a condition or symptoms selected from the group consisting of allergic rhinitis, infectious rhinitis, serous otitis media, sinusitis, pulmonary disease, food allergies, allergic dermatitis, and sneezing, coughing, itching and excess mucous secretion related to allergic reactions~~.

16-17. (Cancelled)

18. (Original) The method of claim 1 wherein the amount of CnT administered per administration is between about 0.1 and about 1000 units per administration.

19. (Original) The method of claim 1 wherein the amount of CnT administered per administration is between about 1 and about 100 units per administration.

20. (Original) The method of claim 1 wherein the amount of CnT administered per administration is between about 1 and about 20 units per administration.

21-24. (Cancelled)

25. (Cancelled)

26. (New) A method of blocking or reducing allergic dermatitis in a mammal resulting from the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) to treat allergic dermatitis, wherein the CnT is isolated or purified from a species of Clostridia selected from the group consisting of C. botulinum, C. butyricum and C. beratti.

27. (New) A method of blocking or reducing allergic rhinitis in a mammal resulting from ~~to~~ the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the nasal administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) to treat allergic rhinitis, wherein the CnT is isolated or purified from a species of Clostridia selected from the group consisting of C. botulinum, C. butyricum and C. beratti and wherein the administration is selected from the group consisting of:.

(i) contact with absorbant pledgets having CnT absorbed thereon;
(ii) contact with biodegradable carrier containing CnT;
(iii) myringotomy of CnT through tympanic membranes;
(iv) injection of CnT into the pterygoplatine space through the palate;
(v) application of a suppository containing CnT;
(vi) an amount of CnT between about 0.1 and about 1000 units per administration;
(vii) an amount of CnT between about 1 and about 100 units per administration; and
(viii) an amount of CnT between about 1 and about 20 units per administration.

28. (New) The method of claim 1, wherein the administration is topical to the nasal cavity.

29. (New) The method of claim 26, wherein the CnT is incorporated in liposomes.

30. (New) The method of claim 26, wherein the CnT is incorporated in a lyophilized powder, liquid solution, cream, ointment, aerosol or liposomes.

31. (New) The method of claim 26, wherein the CnT is administered between about 0.1 and about 1000 units per administration.